Chloe is an award-winning journalist who has specialized in health reporting throughout her career, with a particular focus on women's health and access to medicine. Before joining Generics Bulletin she worked for B2B publishing consortium Verdict, writing about medical technology and pharmaceuticals. Having graduated from the University of York, she went on to train as a journalist with the Press Association.
Latest From Chloe Kent
Stakeholders in Europe have been hesitant to allow interchangeable substitution of biological products, prompting the European Medicines Agency to clarify its stance on the issue.
The Medicines Patent Pool has secured a licensing deal with MedinCell for a long-acting injectable ivermectin drug formulation which could be used to prevent ongoing spread of malaria.
Nichi-Iko still has a long road to recovery ahead as it attempts to get its Toyama plant back on its feet.
IQVIA has published a white paper examining the growing reliance on pharmacy discount cards to pay for prescriptions in the US.
In Vivo's Chloe Kent discussed the future of women in healthcare leadership with Roche executives and Unlocking Eve founders Eva McLellan and Kaye Vitug.
A team of researchers has concluded that in vivo animal studies and large safety and efficacy studies are rarely necessary to license biosimilars.